The study on the mechanism of salidroside in the adjuvant treatment of patients with moderately severe acute pancreatitis

doi:10.11958/20221606

Abstract

Abstract:

Objective To observe the adjuvant therapeutic effect of salidroside on patients with moderately severe acute pancreatitis (MSAP) and explore its mechanism. Methods A total of 60 patients with MSAP were randomly divided into the routine group (30 cases) and the experimental group (30 cases) using the random number table method. A routine treatment method was given to patients in both groups, and patients in the experimental group were additionally treated with salidroside. Serum levels of cysteine-containing aspartate-specific proteases (Caspase)-1, Gasdermin D (GSDMD), absent in melanoma 2 (AIM2), interleukin (IL)-1β and IL-18 were detected by enzyme-linked immunosorbent assay (ELISA) before and 7 days after treatment in both groups. The acute physiology and chronic health evaluation (APACHE) Ⅱ and pancreas-modified CT severity index (MCTSI) scores were evaluated. The time of abdominal pain-relieving and the hospital stay were also recorded in the two groups. Results Compared with 1 d before treatment, serum levels of Caspase-1, GSDMD, AIM2, IL-1β and IL-18 decreased 7 d after treatment in both groups, and serum levels of all above indexes were significantly lower in the experimental group than those in the routine group (P<0.01). Scores of APACHE Ⅱ and pancreas-MCTSI decreased in both groups on 7 d after treatment, and scores of two indexes were significantly lower 7 d after treatment in the experimental group than those in the routine group (P<0.01). The time of abdominal pain-relieving and the hospital stay were all shorter in the experimental group than those in the routine group (P<0.01). Conclusion Salidroside can play a good adjuvant therapeutic effect on patients with MSAP by inhibiting AIM2 inflammasome-mediated pyroptosis.

Key words: pancreatitis, pyroptosis, acute disease, critical care, inflammatory corpuscles, melanoma deficiency factor 2, salidroside

CLC Number:

R576.1

Figures/Tables 4

References 23

[1]	SINONQUEL P, LALEMAN W, WILMER A. Advances in acute pancreatitis[J]. Curr Opin Crit Care, 2021, 27(2):193-200. doi:10.1097/MCC.0000000000000806.
[2]	LEE P J, PAPACHRISTOU G I. New insights into acute pancreatitis[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(8):479-496. doi:10.1038/s41575-019-0158-2.
[3]	MATTA B, GOUGOL A, GAO X, et al. Worldwide variations in demographics,management, and outcomes of acute pancreatitis[J]. Clin Gastroenterol Hepatol, 2020, 18(7):1567-1575.e2. doi:10.1016/j.cgh.2019.11.017.
[4]	韦碧薇, 龚雅慧, 梁志海. 细胞焦亡在急性胰腺炎发病机制中的作用[J]. 临床肝胆病杂志, 2020, 36(8):1905-1908.
	WEI B W, GONG Y H, LIANG Z H. Role of pyroptosis in the pathogenesis of acute pancreatitis[J]. J Clin Hepatol, 2020, 36(8):1905-1908. doi:10.3969/j.issn.1001-5256.2020.08.050.
[5]	ALGABA-CHUECA F, DE-MADARIA E, LOZANO-RUIZ B, et al. The expression and activation of the AIM2 inflammasome correlates with inflammation and disease severity in patients with acute pancreatitis[J]. Pancreatology, 2017, 17(3):364-371. doi:10.1016/j.pan.2017.03.006.
[6]	QIAN J, WANG X, WENG W, et al. Salidroside alleviates taurolithocholic acid 3- sulfate-induced AR42J cell injury[J]. Biomed Pharmacother, 2021, 142:112062. doi:10.1016/j.biopha.2021.112062.
[7]	QIAN J, WANG X H, WEI B Z, et al. Therapeutic effects of salidroside vs pyrrolidine dithiocarbamate against severe acute pancreatitis in rat[J]. J Tradit Chin Med, 2022, 42(1):49-57. doi:10.19852/j.cnki.jtcm.20210707.002.
[8]	WANG X, QIAN J, MENG Y, et al. Salidroside alleviates severe acute pancreatitis- triggered pancreatic injury and inflammation by regulating miR-217-5p/YAF2 axis[J]. Int Immunopharmacol, 2022, 111:109123. doi:10.1016/j.intimp.2022.109123.
[9]	中华医学会外科学分会胰腺外科学组. 急性胰腺炎诊治指南(2014版)[J]. 中华消化外科杂志, 2015, 14(1):1-5.
	Pancreatic Surgery Group of Surgery Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of acute pancreatitis (2014 edition)[J]. Chin J Dig Surg, 2015, 14(1):1-5. doi:10.3760/cma.j.issn.1673-9752.2015.01.001.
[10]	袁鹏. BISAP评分与APACHE Ⅱ 评分在早期预测急性胰腺炎严重程度中的评估比较[D]. 银川: 宁夏医科大学, 2013:1-44.
	YUAN P. A comparative evaluation of BISAP and APACHE Ⅱ scoring system in early prediction of severity in acute pancreatitis[D]. Yinchuan: Ningxia Medical University, 2013:1-44.
[11]	林果为, 王吉耀, 葛均波. 实用内科学[M]. 15版. 北京: 人民卫生出版社, 2017:1644-1650.
	LIN G W, WANG J Y, GE J B. Practice of Internal Medicine[M]. 15th ed. Beijing: People´s Medical Publishing House, 2017:1644-1650.
[12]	FONSECA SEPÚLVEDA E V, GUERRERO-LOZANO R. Acute pancreatitis and recurrent acute pancreatitis: an exploration of clinical and etiologic factors and outcomes[J]. J Pediatr(Rio J), 2019, 95(6):713-719. doi:10.1016/j.jped.2018.06.011.
[13]	袁铁超, 陈国忠, 王婕, 等. 中医多途径治疗重症急性胰腺炎的研究进展[J]. 世界中医药, 2020, 15(16):2515-2518.
	YUAN T C, CHENG G Z, WANG J, et al. Research progress on the treatment of severe acute pancreatitis by multiple approaches of traditional Chinese medicine[J]. World Chinese Medicine, 2020, 15(16):2515-2518. doi:10.3969/j.issn.1673-7202.2020.16.036.
[14]	PU W L, ZHANG M Y, BAI R Y, et al. Anti-inflammatory effects of Rhodiola rosea L.:A review[J]. Biomed Pharmacother, 2020, 121:109552. doi:10.1016/j.biopha.2019.109552.
[15]	ZHENG T, BIAN F, CHEN L, et al. Beneficial effects of rhodiola and salidroside in diabetes:potential role of AMP-activated protein kinase[J]. Mol Diagn Ther, 2019, 23(4):489-498. doi:10.1007/s40291-019-00402-4.
[16]	MAGANI S K J, MUPPARTHI S D, GOLLAPALLI B P, et al. Salidroside - can it be a multifunctional drug?[J]. Curr Drug Metab, 2020, 21(7):512-524.doi:10.2174/1389200221666200610172105.
[17]	ZHANG X, XIE L, LONG J, et al. Salidroside:A review of its recent advances in synthetic pathways and pharmacological properties[J]. Chem Biol Interact, 2021, 339:109268. doi:10.1016/j.cbi.2020.109268.
[18]	LI H Y, LIN Y J, ZHANG L, et al. Progress of pyroptosis in acute pancreatitis[J]. Chin Med J(Engl), 2021, 134(18):2160-2162. doi:10.1097/CM9.0000000000001589.
[19]	CHEN K, WANG S. Ibuprofen alleviates acute pancreatitis-(AP-) induced myocardial injury by inhibiting AIM2[J]. Comput Math Methods Med, 2022, 2022:8801484. doi:10.1155/2022/8801484.
[20]	KANG R, CHEN R, XIE M, et al. The receptor for advanced glycation end products activates the AIM2 inflammasome in acute pancreatitis[J]. J Immunol, 2016, 196(10):4331-4337. doi:10.4049/jimmunol.1502340.
[21]	KUMARI P, RUSSO A J, SHIVCHARAN S, et al. AIM2 in health and disease: inflammasome and beyond[J]. Immunol Rev, 2020, 297(1):83-95. doi:10.1111/imr.12903.
[22]	ZHANG C, CHEN M, CHI Z. Cytokine secretion and pyroptosis of cholesteatoma keratinocytes mediated by AIM2 inflammasomes in response to cytoplasmic DNA[J]. Mol Med Rep, 2021, 23(5):344. doi:10.3892/mmr.2021.11983.
[23]	FIDLER T P, XUE C, YALCINKAYA M, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis[J]. Nature, 2021, 592(7853):296-301. doi:10.1038/s41586-021-03341-5.

组别	Caspase-1			GSDMD
组别	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t
常规组	85.43±12.32	70.65±8.15	13.190^＊＊	94.53±12.64	79.94±8.79	12.460^＊＊
试验组	86.71±12.59	58.37±9.57	28.490^＊＊	95.39±12.87	67.73±10.53	12.510^＊＊
t	0.790	4.430^＊＊		0.490	4.610^＊＊

组别	Caspase-1			GSDMD
组别	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t
常规组	85.43±12.32	70.65±8.15	13.190^＊＊	94.53±12.64	79.94±8.79	12.460^＊＊
试验组	86.71±12.59	58.37±9.57	28.490^＊＊	95.39±12.87	67.73±10.53	12.510^＊＊
t	0.790	4.430^＊＊		0.490	4.610^＊＊

组别	AIM2/（μg/L）			IL-1β/（ng/L）			IL-18/（ng/L）
组别	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t
常规组	2.53±0.30	1.44±0.16	19.340^＊＊	110.80±14.11	86.60±7.18	11.710^＊＊	277.19±37.74	212.21±32.40	16.120^＊＊
试验组	2.41±0.29	0.92±0.12	27.410^＊＊	112.42±14.57	70.17±5.88	14.710^＊＊	278.84±41.06	178.23±20.20	18.840^＊＊
t	1.890	12.260^＊＊		0.610	8.410^＊＊		0.510	4.420^＊＊

组别	AIM2/（μg/L）			IL-1β/（ng/L）			IL-18/（ng/L）
组别	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t
常规组	2.53±0.30	1.44±0.16	19.340^＊＊	110.80±14.11	86.60±7.18	11.710^＊＊	277.19±37.74	212.21±32.40	16.120^＊＊
试验组	2.41±0.29	0.92±0.12	27.410^＊＊	112.42±14.57	70.17±5.88	14.710^＊＊	278.84±41.06	178.23±20.20	18.840^＊＊
t	1.890	12.260^＊＊		0.610	8.410^＊＊		0.510	4.420^＊＊

组别	APACHEⅡ
组别	治疗前			治疗后7 d		t
常规组	10.63±1.52			9.40±1.35		10.790^＊＊
试验组	10.77±1.31			7.07±0.94		16.400^＊＊
t	0.320			7.620^＊＊
组别		胰腺MCTSI评分
组别		治疗前	治疗后7 d		t
常规组		5.33±0.61	4.40±0.50		14.000^＊＊
试验组		5.10±0.85	3.30±0.54		13.800^＊＊
t		0.460	7.040^＊＊